vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and FOX FACTORY HOLDING CORP (FOXF). Click either name above to swap in a different company.
FOX FACTORY HOLDING CORP is the larger business by last-quarter revenue ($376.4M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -0.2%, a 11.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 4.8%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-2.5M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 6.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Fox Factory Holding Corp. is an American company best known for their Fox Racing Shox brand of off-road racing suspension components.
ANIP vs FOXF — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $376.4M |
| Net Profit | $27.5M | $-634.0K |
| Gross Margin | — | 30.4% |
| Operating Margin | 14.1% | 4.0% |
| Net Margin | 11.1% | -0.2% |
| Revenue YoY | 29.6% | 4.8% |
| Net Profit YoY | 367.5% | -113.3% |
| EPS (diluted) | $1.14 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $376.4M | ||
| Q3 25 | $227.8M | $374.9M | ||
| Q2 25 | $211.4M | $355.0M | ||
| Q1 25 | $197.1M | $352.8M | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | $359.1M | ||
| Q2 24 | $138.0M | $348.5M | ||
| Q1 24 | $137.4M | $333.5M |
| Q4 25 | $27.5M | $-634.0K | ||
| Q3 25 | $26.6M | $2.7M | ||
| Q2 25 | $8.5M | $-259.7M | ||
| Q1 25 | $15.7M | $-141.0K | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $4.8M | ||
| Q2 24 | $-2.3M | $5.4M | ||
| Q1 24 | $18.2M | $-3.5M |
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 30.9% | ||
| Q1 25 | — | 28.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 29.9% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 30.9% |
| Q4 25 | 14.1% | 4.0% | ||
| Q3 25 | 15.9% | 4.9% | ||
| Q2 25 | 6.6% | -70.6% | ||
| Q1 25 | 13.3% | 3.2% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 5.2% | ||
| Q2 24 | 3.7% | 5.3% | ||
| Q1 24 | 14.8% | 2.7% |
| Q4 25 | 11.1% | -0.2% | ||
| Q3 25 | 11.7% | 0.7% | ||
| Q2 25 | 4.0% | -73.1% | ||
| Q1 25 | 8.0% | -0.0% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 1.3% | ||
| Q2 24 | -1.7% | 1.6% | ||
| Q1 24 | 13.2% | -1.0% |
| Q4 25 | $1.14 | $-0.02 | ||
| Q3 25 | $1.13 | $0.07 | ||
| Q2 25 | $0.36 | $-6.23 | ||
| Q1 25 | $0.69 | $0.00 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $0.11 | ||
| Q2 24 | $-0.14 | $0.13 | ||
| Q1 24 | $0.82 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $536.7M |
| Stockholders' EquityBook value | $540.7M | $956.0M |
| Total Assets | $1.4B | $2.0B |
| Debt / EquityLower = less leverage | — | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | $71.7M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $536.7M | ||
| Q3 25 | — | $541.8M | ||
| Q2 25 | — | $546.9M | ||
| Q1 25 | — | $552.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $558.4M | ||
| Q2 24 | — | $564.1M | ||
| Q1 24 | — | $370.4M |
| Q4 25 | $540.7M | $956.0M | ||
| Q3 25 | $505.8M | $958.7M | ||
| Q2 25 | $436.8M | $939.9M | ||
| Q1 25 | $418.6M | $1.2B | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | $1.2B | ||
| Q2 24 | $455.8M | $1.2B | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $1.4B | $2.0B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $920.8M | $2.3B | ||
| Q1 24 | $914.5M | $2.2B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.57× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.31× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $5.3M |
| Free Cash FlowOCF − Capex | $29.1M | $-2.5M |
| FCF MarginFCF / Revenue | 11.8% | -0.7% |
| Capex IntensityCapex / Revenue | 0.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $85.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $5.3M | ||
| Q3 25 | $44.1M | $36.8M | ||
| Q2 25 | $75.8M | $680.0K | ||
| Q1 25 | $35.0M | $81.7M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | $14.1M | ||
| Q2 24 | $17.4M | $26.7M | ||
| Q1 24 | $18.3M | $9.4M |
| Q4 25 | $29.1M | $-2.5M | ||
| Q3 25 | $38.0M | $24.6M | ||
| Q2 25 | $71.8M | $-6.5M | ||
| Q1 25 | $32.5M | $69.8M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $3.2M | ||
| Q2 24 | $13.0M | $15.4M | ||
| Q1 24 | $13.7M | $-555.0K |
| Q4 25 | 11.8% | -0.7% | ||
| Q3 25 | 16.7% | 6.6% | ||
| Q2 25 | 34.0% | -1.8% | ||
| Q1 25 | 16.5% | 19.8% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 0.9% | ||
| Q2 24 | 9.4% | 4.4% | ||
| Q1 24 | 10.0% | -0.2% |
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 2.7% | 3.3% | ||
| Q2 25 | 1.9% | 2.0% | ||
| Q1 25 | 1.3% | 3.4% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | 3.0% | ||
| Q2 24 | 3.2% | 3.2% | ||
| Q1 24 | 3.3% | 3.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 13.41× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 4.94× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FOXF
| Specialty Sports Group | $132.7M | 35% |
| Powered Vehicles Group | $125.9M | 33% |
| Aftermarket Applications Group | $117.8M | 31% |
